Skip to main content
Fig. 1 | Journal of Translational Medicine

Fig. 1

From: Selective improvement by rifaximin of changes in the immunophenotype in patients who improve minimal hepatic encephalopathy

Fig. 1

Effects of rifaximin on the PHES in responder and non-responder patients. Values are the mean ± SEM. CTL, controls; NMHE, patients without MHE; MHE, patients with MHE; 3, 6: patients with MHE after 3 and 6 months of rifaximin treatment. Values significantly different from controls are indicated by *. Values significantly different in patients with MHE compared to NMHE are indicated by α. Values significantly different after vs. before treatment are indicated by β (*/α/β p < 0.05; **/αα/ββ p < 0.01; ***/ααα/βββ p < 0.001)

Back to article page

Journal of Translational Medicine

ISSN: 1479-5876

Contact us